A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaawansowany lub przerzutowy guz litego (nowotwór)
- •Potwierdzona mutacja BRAF lub NRAS w komórkach guza
- •Możliwość połykania i wchłaniania leków w postaci tabletek
- •Dobra funkcja narządów wewnętrznych (wątroba, nerki) potwierdzona badaniami
- •Ogólny stan zdrowia pozwalający na leczenie (skala ECOG 0-1)
✗ Disqualifies
- •Wcześniejsze leczenie chemiczne lub celowane wobec białek BRAF, MEK lub MAPK
- •Choroby żołądka lub jelit uniemożliwiające przyjmowanie leków przez usta
- •Aktywna, niekontrolowana infekcja bakteryjna, grzybiczna lub wirusowa
- •Pozytywny wynik testu na SARS-CoV-2
- •Ciąża, karmienie piersią lub potencjalna ciąża
- •Inny nowotór leczony w ciągu ostatnich 3 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (48)
The Angeles Clinic
Los Angeles, United States
UCLA
Los Angeles, United States
University of California San Diego, Moores Cancer Center
San Diego, United States
University of California San Francisco
San Francisco, United States
Sarah Cannon Research Institute Denver
Denver, United States
Mayo Clinic - Florida
Jacksonville, United States
Sarah Cannon Research Institute - Florida Cancer Specialists
Orlando, United States
Mayo Clinic - Rochester
Rochester, United States
Atlantic Health
Morristown, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
NYU Langone
New York, United States
Cleveland Clinic
Cleveland, United States
Sarah Cannon Research Institute-Tennessee Oncology
Nashville, United States
MD Anderson
Houston, United States
Virginia Cancer Specialists
Fairfax, United States
Calvary Mater Hospital Newcastle
Waratah, Australia
Melanoma Institute Australia
Wollstonecraft, Australia
Tasman Health Care
Southport, Australia
Austin Health
Heidelberg, Australia
Linear Clinical Research
Perth, Australia
Harbin Medical University Cancer Hospital
Haerbin, China
Linyi Cancer Hospital
Linyi, China
Beijing University Cancer Hospital
Beijing, China
The Shanghai Pulmonary Hospital
Shanghai, China
Institut Bergonie
Bordeaux, France
Centre Francois Baclesse
Caen, France
CHU de Lille
Lille, France
Centre Leon Berard
Lyon, France
APHM-CHU La Timone
Marseille, France
CHU Nantes-Hotel Dieu
Nantes, France
CHU de Nice - Hôpital Archet 2
Nice, France
APHP - Hôpital St Louis
Paris, France
Hospices Civiles de Lyon - Hôpital Lyon Sud
Pierre-Bénite, France
CHU de Poitiers
Poitiers, France
Oncopole Claudius Regaud
Toulouse, France
Gustave Roussy
Villejuif, France
Istituto Nazionale dei Tumori Fondazione G. Pascale
Naples, Italy
Arance
Barcelona, Spain
NEXT Quirónsalud Madrid
Madrid, Spain
H. Regional de Málaga
Málaga, Spain
H. Virgen Macarena
Seville, Spain
Berrocal
Valencia, Spain
Hospital Quiron Dexeus
Barcelona, Spain
Hospital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, Spain
START Madrid
Madrid, Spain
Hospital General Gregorio Marañón
Madrid, Spain
INCLIVA (Hospital Clinico de Valencia)
Valencia, Spain
National Taiwan University Hospital
Taipei, Taiwan
Trial contact
Data Protection Officer
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.